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Abstract
Fatigue and depression are common co-morbid conditions among people with HIV infection. We 
analyzed a population of HIV-infected adults with depression, who were enrolled in a depression 
treatment trial, to examine the extent to which improvements in depression over time were 
associated with improvements in HIV-related fatigue. Data for this analysis come from a 
randomized controlled trial to evaluate the effectiveness of improved depression treatment on 
antiretroviral adherence. Fatigue was measured using the HIV-Related Fatigue Scale, and 
depressive symptoms were measured with the Hamilton Depression Rating Scale. Participants (n = 
234) were on average nearly 44 years of age and predominantly male, black or African American, 
and unemployed. Individuals who experienced stronger depression response (i.e., greater 
improvement in depression score) had larger decreases in fatigue. However, even among those 
who demonstrated a full depression response, nearly three-quarters continued to have either 
moderate or severe fatigue at 6 and 12 months.
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Fatigue is a debilitating and ubiquitous symptom among people living with HIV [1]. 
Prevalence estimates for fatigue range from 33 to 88 % [2], and for those with fatigue, 
almost 50 % report it as their most debilitating symptom [3]. For people living with HIV, 
fatigue hampers daily activities, as well as mental function and the ability to socialize. As 
the number of people living with HIV long-term continues to increase, strategies to 
effectively manage fatigue are increasingly important.
Among HIV-infected individuals, fatigue is often comorbid with a range of psychosocial 
factors including depression, anxiety, and post-traumatic stress disorder [2]. Of these, 
depression is perhaps the most prevalent, affecting 20–30 % of HIV-infected individuals [4–
6]. Depression has been consistently and strongly associated with HIV-related fatigue [2, 7–
19]. The high co-occurrence of fatigue and depression can be explained in part by the fact 
that fatigue is one of the nine core symptoms of major depressive disorder [20]. However, 
HIV-related fatigue has been described as a condition clinically distinct from depression 
[21–23]. Thus effective depression treatment might be expected to partially ameliorate but 
not fully resolve HIV-related fatigue.
In the present study, we analyzed a population of HIV-infected adults with depression, who 
were enrolled in a depression treatment trial, to examine the extent to which improvements 
in depression over time were associated with improvements in HIV-related fatigue.
Methods
Data for the present analysis come from a randomized controlled trial to evaluate the 
effectiveness of improved depression treatment on antiretroviral adherence (the SLAM 
DUNC Study), described in detail elsewhere [24]. Briefly, HIV-infected patients receiving 
medical care at one of four US infectious disease clinics were eligible to participate if they 
were English speaking, ages 18–65, screened positive for depression on the Patient Health 
Questionnaire-9 (score ≥10) [25], and were confirmed to have current major depressive 
disorder on the Mini International Neuropsychiatric Interview (MINI) [26]. Exclusion 
criteria included history of bipolar or psychotic disorder, failure of two or more adequate 
antidepressant trials in the current major depressive episode, or psychiatric presentation 
requiring immediate hospitalization or other acute intervention [24]. Eligible individuals 
who agreed to participate were randomized to receive either enhanced usual care for 
depression or a depression treatment model called measurement-based care (MBC) [27]. In 
the intervention (MBC) arm, a clinically supervised depression care manager (DCM) 
provided evidence-based antidepressant treatment recommendations to the HIV provider, 
who made final decisions on the depression treatment plan. DCM recommendations focused 
on initiation of antidepressants and dose adjustment based on algorithm-centered depressive 
symptom response and tolerability, but the HIV provider made all final decisions about 
treatment. Participants randomized to the enhanced usual care arm could have also received 
depression treatment from their HIV provider or other sources, but no in-clinic decision 
support was provided by the DCM. All participants provided written informed consent, and 
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ethical approval was provided by Duke University, the University of North Carolina at 
Chapel Hill, and the University of Alabama at Birmingham.
Measures
Fatigue intensity, the primary outcome for this analysis, was assessed at baseline, 6, and 12 
months with the Fatigue Intensity subscale of the HIV-Related Fatigue Scale [10,28]. This 8-
item subscale includes Likert scale-rated items such as the respondent’s level of fatigue 
today and most days, the severity of the fatigue, and the extent to which fatigue has caused 
problems or distress. The summary score can range from 1 to 10. This scale has been 
previously reported to have high internal consistency (Cronbach’s alpha = 0.93) [28]; in this 
sample Cronbach’s alpha was 0.92. A binary version of the summary score was used as a 
secondary outcome, in which individuals were classified as having no fatigue (answers of 1 
or 2 on first 7 questions) or any fatigue (summary score >2). Descriptively we also assessed 
fatigue as a categorical measure, in which individuals were classified as no fatigue, moderate 
fatigue (summary score <7), or severe fatigue (summary score ≥7) [29]. The 3-level measure 
of fatigue was not assessed in multivariable analyses due to limited sample size.
Change in depressive severity, the exposure of interest for this analysis, was defined as the 
relative change in depressive symptom severity at 6 and 12 months, compared to baseline, 
on the Hamilton Depression Rating Scale (HAM-D) [30, 31], which was administered by 
trained assessors blinded to study arm. Cronbach’s alpha for the HAM-D total score in this 
sample was 0.83. The change between baseline and 6 or 12 months was categorized into 
clinically meaningful response categories [32]: full response (≥50 % improvement), partial 
response (25–49 % improvement), and no response (<25 % improvement). Categorization of 
change in depression may enhance clinical interpretability but at the cost of precision; 
continuous measures generally yield narrower confidence intervals and greater statistical 
power. Thus, we also considered percent change in depressive severity from baseline to 6 
and 12 months as a continuous measure.
Potential confounders of interest were identified based on subject matter knowledge and 
included baseline age, coping style, self-efficacy, number of contacts per quarter with mental 
health professionals, and baseline psychiatric comorbidities. Coping styles were assessed 
using the Brief COPE [33, 34] and were collapsed into two summary scales representing 
adaptive (positive reframing, using emotional support, acceptance, religion, active) and 
maladaptive (denial, self-blame, behavioral disengagement, substance use) coping strategies, 
as we have done in prior research [35]. The two scales each ranged from 1 to 4, had high 
internal consistency (α = 0.80 and 0.74 respectively), and showed low correlation 
(correlation coefficient 0–0.14), supporting their conceptualization as two distinct factors. 
Self-efficacy was assessed using the HIV Self-Efficacy questionnaire [36] which contains 6 
subscales. The self-efficacy in management of fatigue subscale was eliminated because of 
overlap with the outcome. Based on exploratory factor analyses, the remaining 5 subscales 
loaded onto two summary scales, one measuring self-efficacy around HIV medication 
adherence, provider communication, and depression management, and the second measuring 
self-efficacy around HIV symptom management and social support. Both summary scales 
ranged from 1 to 10 and had high internal consistency (α = 0.93 and 0.88). Study arm was 
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not included as a potential confounder, since the mechanism by which change in depression 
might improve fatigue was hypothesized to result from interactions with a mental health 
professional and subsequent access to depression treatment and improved coping and self-
efficacy skills, all of which were included in the analysis.
Analysis Sample
For inclusion in the present analysis, participants must have completed a baseline HAM-D 
within 14 days of enrollment, completed one or both of the 6- and 12-month interviews, and 
scored ≥8 on the baseline HAM-D (indicating depressive symptoms not in remission). 
Although all participants met criteria for current major depressive disorder on the MINI at 
the time of eligibility assessment, in some cases participants subsequently endorsed fewer 
depressive symptoms on the HAM-D during their baseline research interview.
Statistical Analysis
We used linear regression with generalized estimated equations to compare mean differences 
in fatigue severity between groups of depressive severity response, accounting for repeated 
measures on each individual. Depressive severity response was considered a categorical 
measure of full, partial or no response in depressive symptoms and as a continuous measure 
with a change of 1 unit corresponding to a 25 % improvement in depressive symptoms. We 
used locally weighted scatterplot smoothing (LOWESS) graphs to assess the assumption of 
linearity of the continuous measure of change in depression with the two measures of fatigue 
considered as outcomes. The distribution of fatigue scores was assessed to ensure it was 
approximately normally distributed using descriptive statistics (mean, median, skew and 
kurtosis). Additionally, we used logistic regression with generalized estimating equations to 
estimate the association between presence of any fatigue (yes or no) over time and 
continuously measured change in depressive severity. The association between presence of 
any fatigue and a categorical measure of depressive severity response was not assessed due 
to small cell sizes that led to lack of convergence. All final multivariable models were 
adjusted for all confounders, unless otherwise noted. The functional form of non-binary 
confounders (i.e., number of mental health contacts per quarter) with the outcome was 
assessed. Log transformations or polynomials were used to relax linearity assumptions when 
necessary. In a sensitivity analysis, we repeated all analyses with a modified HAM-D 
depressive severity score that omitted one item most closely related to the outcome (“How 
has your energy been in the past week? Have you felt tired?”). Statistical analyses were 
performed using Stata 13 (Stata-Corp, College Station, TX).
Results
Of 304 individuals enrolled in the trial, 242 had a baseline HAM-D within 14 days of 
enrollment and scored ≥8 on that HAM-D. Of those, 234 (97 %) completed a 6-month 
and/or a 12-month research interview (159 at 6 months and 127 at 12 months) and are 
included in this analysis.
Participants were on average nearly 44 years of age and predominantly male (70 %), black 
or African American (65 %), and unemployed (74 %). In addition to major depression, for 
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which all participants met criteria, nearly three-quarters of all participants (73 %) also met 
diagnostic criteria for an anxiety disorder, a substance use disorder, or both. On average, 
participants had approximately 2 mental healthcare contacts per quarter and had good 
clinical HIV indicators at baseline (mean CD4 count 607; 70 % with HIV RNA viral load 
<50 copies/mL) (Table 1). Demographic characteristics were similar across categories of 
highest depression response, with a few exceptions. There was a trend towards more mental 
health contacts per quarter and better depression response: those who never responded had 
1.2 contacts, those who partially responded had 1.7 and those who responded had 2.1 
contacts. A larger proportion of individuals who were not employed either partially 
responded (79 %) or responded (78 %), compared to those who did not respond (67 %).
At baseline, the mean fatigue intensity score was 6.9 on a 1–10 scale (Table 2). Nearly all 
individuals experienced either moderate (45 %) or severe (54 %) fatigue, with only 1 % 
reporting no fatigue (Table 2). The mean fatigue score decreased over time for the study 
population as a whole (mean of 5.4 at 6 months and 5.3 at 12 months). The proportion of 
participants experiencing severe fatigue decreased somewhat (33–35 % at 6 and 12 months). 
However, the proportion reporting moderate fatigue increased (54–59 %), and only a small 
minority reported no fatigue at follow-up (8–11 %).
Individuals who experienced stronger depression response (i.e., greater improvement in 
depression score) had larger decreases in fatigue. At 12 months, the mean fatigue score was 
3.3 among those who demonstrated a full depression response, 5.5 among those who 
demonstrated a partial response, and 6.7 among those who demonstrated no response (Fig. 
1). At 12 months, 29 % of those with a full depression response reported no fatigue 
compared to 3 % of those with a partial depression response and 2 % of those with no 
depression response (Table 2). Similar results were seen at 6 months. However, even among 
those who demonstrated a full depression response, nearly three-quarters continued to have 
either moderate or severe fatigue at 6 and 12 months.
In multivariable analyses of fatigue severity, compared to those with no depression response, 
partial depression response was associated with an average decrease of −0.52 points in 
fatigue severity on the 10-point scale (95 % CI −1.10, 0.06) and full depression response 
was associated with an average decrease of −2.01 points in fatigue severity (95 % CI −2.67, 
−1.41). Every 25 % improvement in depressive symptoms was associated with an average 
decrease of −0.40 points in fatigue severity (95 % CI −0.55, −0.26). When fatigue (yes or 
no) was considered as a binary outcome, a 25 % improvement in depression was associated 
with a 48 % reduction in the odds of any fatigue (OR 0.52, 95 % CI 0.32, 0.84) (Table 3).
In a sensitivity analysis using a modified HAM-D depressive severity total score that omitted 
one item asking about fatigue, all point estimates and conclusions about the inclusion of the 
null value in the 95 % confidence interval were substantively unchanged.
Discussion
In this sample of HIV-infected adults with depression participating in a depression treatment 
trial, we found a dose–response relationship between improvements in depression over the 
Barroso et al. Page 5













course of the study and improvements in fatigue. Participants who demonstrated a full 
depression response over 12 months experienced greater improvements in fatigue than those 
demonstrating partial or no depression response, and each 25 % improvement in depressive 
severity was associated with a clinically meaningful improvement in fatigue. However, in 
most cases this improvement represented a shift from severe to moderate fatigue, with 
relatively few participants achieving fatigue remission even among those demonstrating a 
full depression response. Residual symptoms of depression such as fatigue are believed to 
predict a subsequently harder to treat course of depression [37, 38], and they are an indicator 
of a disorder which, in spite of improvement, is still present. This may call for vigorous and 
longer than usual continuation of antidepressant treatment, in order to prevent relapse. There 
is also good evidence for the use of cognitive therapy as an adjunct [38].
Overall, the study population mirrored the sociodemographics of the HIV epidemic in the 
Deep South, with a majority of participants being African American and male, and three out 
of four being unemployed. It is important to note that participants generally were clinically 
stable and relatively healthy with regard to their HIV infection. At baseline, nearly all 
participants were moderately or severely fatigued, an expected finding given that depression 
was a criterion for entry into the study.
There is some evidence that the multiple comorbidities of depression, such as fatigue, can be 
explained by neuroinflammatory, oxidative and nitrosative stress pathways [39]. Depression 
may be the clinical expression of peripheral cell-mediated activation, inflammation, and 
induction of oxidative and nitrosative stress pathways and of central microglial activation, 
decreased neurogenesis, and increased apoptosis. According to this model, these pathways 
underpin the pathophysiology of depression; the pathways detect illnesses such as HIV 
infection as threats and respond by signaling these threats as melancholy, anxiety, fatigue, 
and somatic symptoms. Depression contributes to increased neuroinflammatory burden and 
may therefore drive the inflammatory and degenerative progression [39]. This model would 
suggest that aggressive treatment of depression may help to decrease HIV-related fatigue. 
This hypothesis is partially supported by our data, as stronger depression response was 
associated with greater improvements in fatigue. However, a large proportion of participants 
in this study remained moderately or severely fatigued even after demonstrating a full 
depression response. These same pathways have been implicated in chronic fatigue 
syndrome and idiopathic fatigue [40], which may explain why treating depression will not 
fully resolve fatigue in HIV infection: chronic inflammation is key and must be addressed.
Few interventions have been developed to ameliorate HIV-related fatigue, but when 
implemented, they often improve depressive symptoms as well. Aerobic and resistance 
training was shown to decrease depression but not fatigue when compared to a sedentary 
group [17]. Rabkin et al. evaluated the efficacy and safety of armodafinil to treat HIV-related 
fatigue and assessed its effect on depressive symptoms. They found that armodafinil did not 
reduce depressive symptoms in the absence of improved energy. However, among 
participants with a depressive disorder at study entry whose energy improved, 82 % 
experienced improved mood as well [41]. Given the strong relationship between 
psychosocial factors and fatigue, Jong and colleagues [2] in a comprehensive review 
recommended research comparing the effect of medication (antidepressants, anxiolytics) and 
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behavioral interventions (cognitive-behavioral therapy, relaxation therapy, graded exercise 
therapy) to direct the best treatment strategy. The persistent coexistence of fatigue and 
depression [42] may need to be treated with psychosocial interventions in addition to 
medications.
One limitation of this study is the subjective nature of the measures of both the primary 
exposure (depressive severity) and outcome (fatigue). Both, however, were measured with 
well-validated scales by trained interviewers, and the HAM-D depressive severity measure is 
interviewer-scored rather than self-administered. A potential limitation is that the sample 
had relatively well-controlled HIV infection, so the results may not be generalizable to those 
who are more ill. Another limitation, in terms of generalizability, is that the study sample is 
restricted to individuals willing to enroll in a depression treatment trial. It is possible that 
individuals with more severe depression, and thus greater potential for response, chose to 
enroll in the study, which may have enhanced the relationship between change in depression 
and fatigue. A key strength of this study, in addition to its validated, longitudinal measures 
of depressive severity and fatigue, is the design as an additional analysis of a problematic 
symptom that may have been impacted by a depression treatment trial. Most prior studies of 
the relationship between depression and fatigue have been either cross-sectional or 
observational. The present analysis offers one of the first opportunities to explore the 
longitudinal impact of depression treatment on fatigue severity.
The findings reported here advance our understanding of the relationship between fatigue 
and depression among HIV-infected individuals and provide a new direction in terms of 
treatment of HIV-related fatigue. Aggressive treatment of depression may have the potential 
to improve fatigue in some HIV-infected individuals. The alleviation of both of these 
frequent conditions will mean an improved quality of life for those with HIV infection. A 
recent report found that stressful life events preceded depression and anxiety in a cohort of 
fatigued HIV-infected individuals who were followed for 3 years [18], so it may be that 
psychosocial interventions such as peer-assisted approaches, mindfulness-based stress 
reduction, and group approaches combined with aggressive psychopharmacological 
treatment may yield the most significant results. Jong et al.’s recommendation [2] to include 
behavioral interventions to treat HIV-related fatigue is sound, and those interventions likely 
will have the greatest impact if we can start with the aggressive treatment of depression, so 
our patients can participate fully in behavioral change. Although we may not yet fully 
understand the root cause of fatigue in HIV infection, there is hope that it is a modifiable 
condition.
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Fatigue intensity over 12 months, stratified by change in depressive symptoms from 
baseline. No/partial/full response: <25 %/ 25–49 %/>49 % improvement in depressive 
symptoms relative to baseline. The group categorized as “Response” at baseline includes all 
those who demonstrated full response at either 6 or 12 months. The group categorized 
“Partial response” at baseline includes all those who demonstrated partial response at either 
6 or 12 months but never demonstrated full response. The group categorized as “No 
response” at baseline includes all those who never demonstrated partial or full response at 
either 6 or 12 months. At 6 and 12 months, participants are classified by their depression 
response status at that time point
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Table 1
Baseline sociodemographic and clinical characteristics of 234 HIV-infected adults
Characteristic N (%) or Mean (SD)
Age 43.5 (10.1)
Gender
  Male 164 (70.1)
  Female 70 (29.9)
Race
  White or Caucasian 73 (31.2)
  Black or African American 152 (65.0)
  Other 9 (3.8)
Currently employed
  Yes 61 (26.2)
  No 172 (73.8)
Psychiatric comorbidities
  Depression only 63 (26.9)
  Comorbid anxiety 114 (48.7)
  Comorbid substance abuse or dependence 18 (7.7)
  Comorbid anxiety and substance abuse or dependence 39 (16.7)
Depressive severity (HAM-D) (range 0–52) 20.9 (6.1)
Adaptive coping (range 1:4) 2.7 (0.6)
Maladaptive coping (range 1:4) 2.1 (0.6)
Self-efficacy, scale 1 (range 1:10)a 5.5 (1.7)
Self-efficacy, scale 2 (range 1:10)a 9.3 (1.2)
Number of mental health contacts per quarter, over follow-up 1.8 (6.3)
CD4 count, cells/mm3 607 (371.5)
HIV RNA viral load <50 c/mL 151 (69.6 %)
a
Scale 1 self efficacy around HIV medication adherence and provider communication. Scale 2 self efficacy around depression management, HIV 
symptom management, and social support
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Table 2
Fatigue severity and depression over time
Overall Change in depressive severity
No response Partial response Full response
Baseline (n = 234)
  Fatigue score, mean (SD)a 6.9 (1.9) 7.1 (1.8) 7.0 (2.0) 6.7 (2.0)
    No fatigue, n (%) 3 (1.3) 1 (1.0) 0 (0.0) 2 (2.1)
    Moderate fatigue (<7), n (%) 105 (45.3) 42 (43.8) 18 (42.9) 45 (47.9)
    Severe fatigue (≥7), n (%) 124 (53.5) 53 (55.2) 24 (57.1) 47 (50.0)
6 months (n = 159)
  Fatigue score, mean (SD)a 5.4 (2.6) 6.4 (2.3) 6.0 (2.2) 3.4 (2.2)
    No fatigue, n (%) 13 (8.3) 3 (3.9) 0 (0.0) 10 (22.7)
    Moderate fatigue (<7), n (%) 92 (58.6) 39 (51.3) 23 (62.2) 30 (68.2)
    Severe fatigue (≥7), n (%) 52 (33.1) 34 (44.7) 14 (37.8) 4 (9.1)
12 months (n = 127)
  Fatigue score, mean (SD)a 5.3 (2.7) 6.7 (2.1) 5.5 (2.4) 3.3 (2.4)
    No fatigue, n (%) 14 (11.2) 1 (1.9) 1 (3.3) 12 (28.6)
    Moderate fatigue (<7), n (%) 67 (53.6) 24 (45.3) 17 (56.7) 26 (61.9)
    Severe fatigue (≥7), n (%) 44 (35.2) 28 (52.8) 12 (40.0) 4 (9.5)
a
2 people missing fatigue scores at all time points
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Table 3
Adjusted association of improvement in depression with fatigue intensity over 12 months
Change in depressive severity Fatigue severity (range 1–10)a
Adjusted mean difference (95 % CI)
Any fatigue (yes/no)b
Adjusted odds ratio (95 % CI)
Categorical
  No response 0.00 (ref) n/a
  Partial response −0.52 (−1.10, 0.06) n/a
  Full response −2.04 (−2.67, −1.41) n/a
Continuous
  Per 25 % improvement in symptoms −0.40 (−0.55, −0.26) 0.52 (0.32, 0.84)
NB: HIV medication adherence, provider communication and depression management self-efficacy were dropped from the model because high 
correlation with adaptive coping led to unstable standard errors
a
Adjusted for: baseline age, adaptive coping, maladaptive coping, self-efficacy, number of mental health contacts per quarter and baseline 
psychiatric comorbidities
b
Adjusted for: baseline age, adaptive coping, maladaptive coping, social support self-efficacy (only), number of mental health contacts per quarter 
and baseline psychiatric comorbidities
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